A number of key clinical and preclinical study results into potential Parkinson’s disease (PD) therapeutics were announced at the International Congress of Parkinson’s Disease and Movement Disorders. Unexpected early results for allosteric enzyme modulator Gain Therapeutics shared encouraging early results from the Phase Ib clinical study of GT-02287 in people with PD with or without […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!